Renovo scar revision drug Juvista fails to meet primary endpoint
Following the result, Renovo will conduct further exploratory analysis and determine the future of the Juvista development programme. The double blind, placebo controlled trial was designed to evaluate
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.